Life science news 20 July 2026: the FDA approves the first oral PCSK9 inhibitor for high cholesterol, Eli Lilly makes the largest psychedelics deal in Big Pharma history, and a first-in-class breast cancer therapy wins regulatory clearance in a landmark week for pharma, biotech and healthcare.
Merck announced on 16 July that the US Food and Drug Administration has approved Lipfendra (enlicitide) as the first oral PCSK9 inhibitor for reducing LDL cholesterol in adults with hypercholesterolaemia, including heterozygous familial hypercholesterolaemia. Lipfendra is a novel macrocyclic peptide taken as a once-daily 20 mg tablet, offering a pill-based alternative to injectable PCSK9 therapies such as evolocumab and alirocumab that have historically faced uptake barriers linked to injection-based dosing. The approval was supported by the Phase 3 CORALreef Lipids and CORALreef HeFH trials, in which Lipfendra reduced LDL cholesterol by a placebo-adjusted 56 per cent and 59 per cent respectively at 24 weeks, matching the efficacy of existing injectable agents. Financial analysts estimate the drug has the potential to generate more than $2 billion in annual sales within a few years of launch, with Merck beating AstraZeneca’s rival oral PCSK9 candidate to market.
Eli Lilly announced on 16 July that it will acquire AtaiBeckley, a clinical-stage biopharmaceutical company developing psychedelic-based treatments for mental health conditions, for $2.8 billion in cash upfront with an additional $1 billion in potential development and regulatory milestone payments. The deal, the largest psychedelics acquisition by a major pharmaceutical company to date, gives Lilly access to BPL-003, a DMT-related nasal spray currently in Phase 3 trials for treatment-resistant depression, with pivotal data expected in early 2029. AtaiBeckley is also developing a DMT buccal film and an MDMA-related compound for other psychiatric indications. The acquisition extends Lilly’s long-standing neuroscience franchise and comes amid growing policy and regulatory interest in psychedelic-based treatments for depression and post-traumatic stress disorder.
The FDA approved gedatolisib on 14 July, to be marketed as Revtorpyk by Celcuity, for adults with hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer without a PIK3CA mutation detected, following progression on or after at least one line of endocrine therapy. Revtorpyk is the first approved therapy that inhibits all class I PI3K isoforms and both mTOR complexes mTORC1 and mTORC2. In the Phase 3 VIKTORIA-1 trial, the combination of gedatolisib with palbociclib and fulvestrant reduced the risk of disease progression or death by 76 per cent compared with fulvestrant alone, while gedatolisib with fulvestrant reduced the risk by 67 per cent. Celcuity plans to submit a supplemental application in the third quarter of 2026 seeking approval for PIK3CA-mutant breast cancer, based on data presented at the 2026 ASCO Annual Meeting.
AstraZeneca announced on 14 July that it has entered into an exclusive global licence agreement with Shanghai-based Dizal Pharmaceutical for Zegfrovy (sunvozertinib), a novel oral irreversible EGFR inhibitor for patients with non-small cell lung cancer harbouring exon 20 insertion mutations. Under the terms of the agreement, AstraZeneca will pay $600 million upfront with up to $900 million in additional development, regulatory and sales milestone payments, alongside tiered royalties on global net sales. Zegfrovy is already approved in the United States and China as a second-line treatment after platinum-based chemotherapy. In the Phase 3 WU-KONG28 trial, sunvozertinib demonstrated a median progression-free survival of 10.3 months compared with 7.5 months for chemotherapy. Dizal has filed for expanded use as a first-line treatment in both countries, with Breakthrough Therapy Designation secured from the FDA.
In further life science news 20 July 2026, the week also brought a key regulatory conversion for a kidney disease therapy, strong quarterly results from one of the world’s largest healthcare companies, and two significant developments from the UK’s medicines regulator.
Novartis announced on 17 July that the FDA has granted traditional approval to Fabhalta (iptacopan) to slow kidney function decline in adults with primary IgA nephropathy at risk of disease progression, converting the accelerated approval first granted in August 2024. Fabhalta is the first and only complement inhibitor shown to significantly slow the rate of kidney function loss in primary IgA nephropathy, a chronic immune-mediated disease in which up to half of patients with persistent proteinuria progress to kidney failure within 10 to 20 years. The conversion was supported by final two-year data from the Phase 3 APPLAUSE-IgAN trial, published in The New England Journal of Medicine in March 2026, which demonstrated a 48 per cent slowing of kidney function decline compared with placebo.
Johnson & Johnson reported on 15 July that second-quarter 2026 sales reached $25.3 billion, up 6.6 per cent year on year, beating analyst expectations of approximately $25.05 billion. Adjusted earnings per share rose 4.7 per cent to $2.90, also ahead of consensus forecasts. Growth was driven by immunology drug Tremfya and cancer blockbuster Darzalex, which together more than offset erosion from older products. The company raised its full-year 2026 guidance, with estimated reported sales of approximately $101.1 billion at the midpoint, putting Johnson & Johnson on track to surpass $100 billion in annual revenue for the first time in its 140-year history. Chairman and CEO Joaquin Duato described the results as a demonstration of the depth of the company’s portfolio and the momentum in its pipeline.
The UK’s Medicines and Healthcare products Regulatory Agency published its 2025-26 Annual Report and Accounts on 16 July, confirming that it met or exceeded all statutory performance targets during the year. The report, which has been laid before Parliament, shows that the MHRA approved 921 medicinal products for use including 39 new medicines, while assessing 100 per cent of clinical trial applications and national medicines licence applications within target timelines. The report also highlighted new Clinical Trials Regulations, which came into force in April 2026, including a 14-day first assessment for phase 1 clinical trials designed to make it faster and easier to run trials in the UK. The MHRA will also publish its new MHRA2030 Strategy later this year, setting out how it intends to strengthen patient safety, support innovation and develop as a modern, science-led regulator.
The MHRA also published on 17 July the programme report from the second phase of its AI Airlock regulatory sandbox, setting out technical and regulatory insights from testing seven AI-enabled medical devices across three challenge areas between April 2025 and May 2026. The programme, the first dedicated regulatory sandbox for AI medical devices established by any national regulator, produced recommendations for changes to the UK’s regulatory and support framework for AI as a medical device. Key findings addressed risk classification, change management planning, and bias and fairness metrics for adaptive AI systems. The report will inform the work of the National Commission into the Regulation of AI in Healthcare, which brings together regulators, clinicians, patient representatives and technology companies to advise on the future of AI oversight in the NHS and wider UK health system.
That’s your life science news digest for 20 July 2026, back next Monday with the latest from pharma, biotech and healthcare at www.lifesciencedaily.news. Catch up on the 13 July news roundup.
